WACKER BIOSOLUTIONS
Sales for 2023 at WACKER BIOSOLUTIONS edged up 1.8 percent to €337.2 million, slightly above the prior-year level (2022: €331.1 million). While growth was robust in biopharmaceuticals, sales of established products slowed amid lower prices and volumes. Regionally, sales climbed strongly in Asia and Europe. In the Americas, sales declined year over year.
EBITDA of €6.5 million was markedly lower than the year before (2022: €16.7 million). Integration and upfront costs at the León and Halle sites burdened EBITDA. The EBITDA margin was 1.9 percent (2022: 5.0 percent).
Capital expenditures increased significantly year over year, rising from €102.6 million to €155.5 million in 2023. CAPEX focused on the construction of a new mRNA competence center in Halle and on expanding the Amsterdam site. In early May, WACKER strengthened its biotechnology business by acquiring ADL BioPharma S.L.U. in León (Spain). The company’s workforce of around 300 were taken on in the acquisition. As of December 31, 2023, the number of employees at the division was 1,191 (Dec. 31, 2022: 835).
|
|
|
|
|
||||||
€ million |
|
2023 |
|
2022 |
|
2021 |
|
2020 |
|
2019 |
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Total sales |
|
337.2 |
|
331.1 |
|
296.4 |
|
246.1 |
|
243.0 |
EBITDA |
|
6.5 |
|
16.7 |
|
38.6 |
|
38.1 |
|
31.1 |
EBITDA margin (%) |
|
1.9 |
|
5.0 |
|
13.0 |
|
15.5 |
|
12.8 |
EBIT |
|
-20.1 |
|
-4.7 |
|
20.7 |
|
21.6 |
|
14.0 |
Capital expenditures |
|
155.5 |
|
102.6 |
|
33.5 |
|
19.9 |
|
13.2 |
R&D expenses |
|
5.5 |
|
4.8 |
|
5.6 |
|
5.7 |
|
6.4 |
Employees (December 31, number) |
|
1,191 |
|
835 |
|
751 |
|
764 |
|
754 |
